Why the study?
Clinical trials of antioxidant and anti-inflammatory therapies in chronic heart failure have yielded mostly disappointing or preliminary results, warranting a comprehensive review to guide future research.
Design
Review
Authors
Loading...
Mostly disappointing antioxidant trial results warrant caution in heart failure; leaves open targeted therapies including vitamin C, elamipretide, coenzyme Q10, and anakinra.
This review highlights the pathophysiological roles of oxidative stress and inflammation in heart failure progression and underscores the need for further research into targeted antioxidant and anti-inflammatory therapies.
Aimo et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: